ImmunoPCR, Microarray Diagnostics, and a Whole New Breed of Institute | GenomeWeb

A year ago in Genome Technology, a feature story checked into immunoPCR as an up-and-coming diagnostic tool. Only 15 years old, the technique couples an antibody-based detection assay with real-time PCR, allowing for the detection of proteins and viruses in very small concentrations. At the time, TATAA's Mikael Kubista was tweaking his PSA test to use immunoPCR instead of ELISA, and just one company — Chimera Biotec — was selling customized immunoPCR kits.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.